{"entity":{"id":"idea-shared-kras-vaccine-adjuvant","kind":"idea","name":"Off-the-shelf KRAS vaccines after pancreatic cancer surgery","aka":[],"tldr":"Almost every pancreatic cancer shares one of a handful of KRAS mutations. A pre-made vaccine against them could be given to every patient after surgery.","summary":"Almost every pancreatic cancer carries one of a handful of KRAS mutations, so this idea gives a pre-made KRAS vaccine to every patient after surgery, enriching for MRD-positive disease. Tumour burden is low after resection, the neoantigen is shared, ctDNA can enrich and monitor, and RAS inhibitors such as daraxonrasib may increase antigen presentation. ELI-002 7P from Elicio induced KRAS-specific T cells in phase 1 and is in the randomised AMPLIFY-7P phase 2, whereas personalised vaccines such as autogene cevumeran work but take weeks and cost more. The test is a phase 2/3 with ctDNA-positive enrichment and a recurrence-free survival endpoint. At early-clinical maturity it addresses the bottleneck The undruggable drivers.","asOf":"2026-09-04","links":[{"label":"Pant et al., AMPLIFY-201: lymph-node-targeted mutant KRAS amphiphile vaccine in pancreatic and colorectal cancer (Nature Medicine 2024)","url":"https://doi.org/10.1038/s41591-023-02760-3"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal"],"sections":[],"technologies":["shared-antigen-vaccine","mrd-testing","kras-inhibitors"],"targets":["kras"],"drugs":["daraxonrasib","autogene-cevumeran"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["codebreak-300","nct07252232","nct07491445","nct07621718","rasolute-302"],"people":[],"bottlenecks":[],"keyPapers":["paper-pant-nat-med","paper-kras-colorectal-j-clin-oncol-2008","paper-kras-colorectal-j-clin-oncol-2011","paper-kras-colorectal-j-clin-oncol-2010"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Adjuvant KRAS peptide/mRNA vaccination reduces recurrence in resected PDAC with MRD-positive disease, with T-cell response magnitude predicting benefit.","rationale":"Shared neoantigen, low tumour burden post-surgery, ctDNA to enrich and monitor; complements RAS inhibitors that may increase antigen presentation.","test":"Run a phase 2/3 with ctDNA-positive enrichment and an RFS endpoint; explore combination with daraxonrasib.","maturity":"early-clinical"},"route":"/ideas/idea-shared-kras-vaccine-adjuvant/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/"}],"trial":[{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/"},{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/"},{"id":"nct07252232","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07252232/"},{"id":"nct07491445","kind":"trial","name":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07491445/"},{"id":"nct07621718","kind":"trial","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","route":"/trials/nct07621718/"}],"paper":[{"id":"paper-kras-colorectal-j-clin-oncol-2011","kind":"paper","name":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2011/"},{"id":"paper-pant-nat-med","kind":"paper","name":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","route":"/key-papers/paper-pant-nat-med/"},{"id":"paper-kras-colorectal-j-clin-oncol-2010","kind":"paper","name":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2010/"},{"id":"paper-kras-colorectal-j-clin-oncol-2008","kind":"paper","name":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2008/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}],"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}]}}